11-May-2011 - Phylogica Ltd

Phylogica and Pepscan enter collaboration to optimise therapeutic phylomer drug candidates

Phylogica Ltd and Pepscan Therapeutics announced that they have entered a Research Collaboration and Option Agreement to evaluate the combination of their complementary peptide technologies for drug discovery. Under the terms of the agreement, Pepscan using its CLIPS technology will work with Phylogica to optimise novel therapeutic Phylomer drug candidates against CD40-ligand for the treatment of rheumatoid arthritis, autoimmune diseases and inflammatory disorders. Phylogica will also have an option to expand the collaboration to include an undisclosed number of other disease-associated targets. Financial details were not disclosed

Phylogica’s CEO, Dr Paul Watt, said: "We are excited to be working with Pepscan, which has world-class technology for improving the activity and stability of therapeutic peptides. We strongly believe that the combination of Pepscan’s CLIPS technology with our potent Phylomer peptides will further enhance our ability to generate breakthrough drug candidates against difficult-to-treat diseases.”

Dr Wim Mol, CEO of Pepscan, said: "We jointly recognise the perfect match of our combined technologies - Phylogica providing truly innovative peptide leads, and Pepscan applying its state-of-the-art CLIPS technology for peptide lead optimisation. We therefore believe that this agreement only forms the start of a promising and productive relationship between our two companies”.

Facts, background information, dossiers
  • drug candidates
More about Phylogica
  • News

    Phylogica Peptide Fusion Kills Aggressive Breast Cancer Cells

    A pilot study by Associate Professor Pilar Blancafort, a member of the Harry Perkins Institute of Medical Research, shows that Phylogica’s cell penetrating peptides (CPPs) linked with the Omomyc drug kill aggressive drug resistant breast cancer cells in vivo.Professor Blancafort also observ ... more

    Phylogica enters into Research and Licensing Agreement with Genentech

    Phylogica Ltd  announced that it has extended its collaboration with Genentech by entering into a Research and Licensing agreement to discover novel antibiotics. Phylogica  will  employ  its  Phylome® drug  discovery  platform,  including  its  proprietary  cellpenetrating  peptide  discove ... more

    Phylogica licenses technology to Janssen Biotech, Inc.

    Phylogica Ltd  announced a Collaboration and Option agreement with Janssen Biotech, Inc., to discover new classes of drugs derived from Phylogica’s Phylomer® peptide platform. In the initial stage of the collaboration, Phylogica will identify cell-penetrating Phylomer® peptides. Under the t ... more

More about Pepscan Therapeutics
  • News

    Pepscan signs multi-target agreement for antibody discovery

    Pepscan Therapeutics announced a multi-target research agreement with an undisclosed US-based antibody discovery company. Under the agreement Pepscan using its CLIPS platform and other protein mimicry technologies will work with the partner in the discovery of novel antibodies. Under the te ... more

    Pepscan Therapeutics achieves milestones in research collaboration with Janssen R&D Irelad

    Pepscan Therapeutics B.V. announced that it has achieved  two milestones in the Research Collaboration with Janssen R&D Ireland, formerly Tibotec Pharmaceuticals, and received undisclosed payments. In the collaboration, Pepscan has discovered novel peptides with potential therapeutic utilit ... more

    Pepscan appoints new Chief Business Officer

    Pepscan Therapeutics announced the appointment of Michiel Lodder as Chief Business Officer. Dr. Lodder joins Pepscan from Octoplus, where he held the position of Senior Manager Business Development, responsible for licensing, partnering, and alliance management activities.Michiel Lodder hol ... more

  • Companies

    Pepscan Therapeutics

    Pepscan Therapeutics is a product focused immunotherapy company based in the Netherlands. It has developed a pipeline of therapeutic vaccine and antibody programs of which the most advanced is in Phase II clinical testing. Pepscan's proprietary CLIPS(tm) technology has been proven to yield ... more